TG Therapeutics Inc - Asset Resilience Ratio

Latest as of June 2026: 4.25%

TG Therapeutics Inc (TGTX) has an Asset Resilience Ratio of 4.25% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TG Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$69.67 Million

Cash + Short-term Investments

Total Assets

$1.64 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2025)

This chart shows how TG Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TG Therapeutics Inc (TGTX) total assets.

Liquid Assets Composition Over Time

This chart breaks down TG Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TG Therapeutics Inc (TGTX) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$69.67 Million	4.25%
Total Liquid Assets	$69.67 Million	4.25%

Asset Resilience Insights

Limited Liquidity: TG Therapeutics Inc maintains only 4.25% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

TG Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare TG Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Vaxcyte Inc NASDAQ:PCVX	Biotechnology	41.54%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	38.51%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%

Annual Asset Resilience Ratio for TG Therapeutics Inc (2003–2025)

The table below shows the annual Asset Resilience Ratio data for TG Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	5.91%	$62.82 Million	$1.06 Billion	-16.79pp
2024-12-31	22.69%	$131.11 Million	$577.69 Million	-15.10pp
2023-12-31	37.80%	$124.58 Million	$329.59 Million	+7.12pp
2022-12-31	30.67%	$59.37 Million	$193.57 Million	+26.49pp
2021-12-31	4.18%	$15.88 Million	$379.63 Million	-4.13pp
2020-12-31	8.31%	$51.99 Million	$625.64 Million	-8.74pp
2019-12-31	17.05%	$27.80 Million	$163.01 Million	-15.06pp
2018-12-31	32.11%	$26.85 Million	$83.62 Million	+3.36pp
2017-12-31	28.75%	$28.00 Million	$97.38 Million	-7.49pp
2016-12-31	36.24%	$19.85 Million	$54.78 Million	+16.71pp
2015-12-31	19.53%	$22.17 Million	$113.47 Million	-7.05pp
2014-12-31	26.59%	$23.06 Million	$86.75 Million	+16.31pp
2013-12-31	10.28%	$4.95 Million	$48.11 Million	--
2012-12-31	0.00%	$0.00	$22.07 Million	--
2011-12-31	0.00%	$0.00	$15.91 Million	--
2008-12-31	58.45%	$730.00K	$1.25 Million	+49.46pp
2005-12-31	8.99%	$1.01 Million	$11.21 Million	-70.91pp
2004-12-31	79.90%	$4.51 Million	$5.65 Million	+75.39pp
2003-12-31	4.52%	$352.15K	$7.80 Million	--

pp = percentage points

About TG Therapeutics Inc

NASDAQ:TGTX USA Biotechnology

Market Cap

$8.55 Billion

Market Cap Rank

#2555 Global

#930 in USA

Share Price

$55.85

Change (1 day)

+5.30%

52-Week Range

$26.94 - $59.06

All Time High

$59.06